Magdalena Biosciences, Inc.
- Biotech or pharma, therapeutic R&D
Magdalena Biosciences, Inc (Magdalena), a Delaware corporation based in California and Canada, seed funded by OSP, has developed a paradigm shifting approach to drug development, reducing the time from project initiation to POC clinical trial commencement to 18-24 months (vs 4-8 years for small molecules), saving time, money but, more importantly, improving the probability of success through the development of FDA- approved botanical drugs with a focus on plants with a medicinal history of use, frequently for neuropsychiatric and weight maintenance indications. Drug candidates ready to enter clinic in 2025/2026 address the potential multi-billion $ unmet needs of cognitive deficit in schizophrenia, ADHD, positive/negative symptoms in schizophrenia markets and weight maintenance through appetite suppression following GLP-1 agonists. Magdalena, a JV with support from parent companies Jaguar Health (JAGX) and Filament Health (FLHLF), has ethnobotanical and drug development expertise.
Address
DoverDelaware
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}